Vivet Therapeutics Funding: $41M Raised, Series A (2024)

Vivet Therapeutics funding overview

Vivet Therapeutics is based in Paris, France. Vivet Therapeutics has raised $41M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in July 2024. The round record for Vivet Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Novartis Venture Fund, Columbus Venture Partners, Roche Venture Fund, HealthCap, Kurma Partners, Ysios Capital and 1 others. 7 distinct backers are named across the disclosed rounds.

Vivet Therapeutics at a glance

Total raised: $41M
Latest round: Series A
Latest round date: July 2024
Headquarters: Paris, France
Notable investors: Novartis Venture Fund, Columbus Venture Partners, Roche Venture Fund, HealthCap, Kurma Partners, Ysios Capital, Pfizer

Frequently asked about Vivet Therapeutics funding

How much has Vivet Therapeutics raised?: Vivet Therapeutics has raised $41M in total disclosed funding across the rounds on record.
Who has invested in Vivet Therapeutics?: Novartis Venture Fund, Columbus Venture Partners, Roche Venture Fund, HealthCap, Kurma Partners, Ysios Capital are named among the investors backing Vivet Therapeutics.
What was the latest Vivet Therapeutics funding round?: The most recent disclosed round is a Series A, announced in July 2024.
Where is Vivet Therapeutics based?: Vivet Therapeutics is based in Paris, France.
When did Vivet Therapeutics last raise?: The last disclosed Vivet Therapeutics round closed in July 2024 at Series A.

Every Vivet Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Paris at a similar stage.

Vivet Therapeutics Funding: $41M Raised, Series A (2024)

Vivet Therapeutics funding overview

Vivet Therapeutics at a glance

Frequently asked about Vivet Therapeutics funding

Companies related to Vivet Therapeutics (36)

Browse related funding lists (8)